1. Xen 63 versus Preserflo MicroShunt implant in patients with primary open-angle glaucoma
- Author
-
José María Martínez-de-la-Casa, Antonio Pascual-Santiago, Laura Morales-Fernandez, Federico Saez-Frances, Sofia Garcia-Saenz, Noemi Guemes-Villahoz, Ruben Sanchez-Jean, Carmen Mendez, and Julian Garcia-Feijoo
- Subjects
Xen 63 ,Preserflo ,MicroShunt ,Glaucoma ,MIGS ,IOP ,Medicine ,Science - Abstract
Abstract This study compared the efficacy safety profiles of the Xen 63 and Preserflo MicroShunt devices, both standalone, in patients with primary open-angle glaucoma (POAG). It is a retrospective and single-center study conducted on consecutive on patients with medically uncontrolled POAG who underwent either a standalone Xen 63 or a standalone Preserflo and had a 12-month follow-up visit. The primary outcome was the mean IOP at month-12. Sixty eyes were included, 30 eyes in each Xen 63 and Preserflo groups, respectively. Preoperative IOP was significantly lowered from 20.8 ± 3.6 mmHg and 19.1 ± 3.8 mmHg to 14.2 ± 4.5 mmHg and 12.8 ± 2.3 mmHg in the Xen 63 and Preserflo groups, respectively (p
- Published
- 2025
- Full Text
- View/download PDF